Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-19T04:38:24.582Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacogenetic drug use in young danish individuals with severe mental disorders

Published online by Cambridge University Press:  13 August 2021

C. Lunenburg ,
K. Ishtiak-Ahmed ,
T. Werge  and
C. Gasse
C. Lunenburg
Affiliation:
Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark
K. Ishtiak-Ahmed
Affiliation:
Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark
T. Werge
Affiliation:
Institute Of Biological Psychiatry, Mental Health Center Sct. Hans, Copenhagen, Denmark
C. Gasse*
Affiliation:
Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Centre For Integrated Register-based Research, Aarhus University, Aarhus, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. PGx guidelines for psychotropic drugs are available (PGx drugs), but PGx testing is used only limitedly in psychiatric clinical practice.

Objectives

The aim of this study is to pinpoint different aspects of PGx drug use in the population, to support clinical uptake of PGx.

Methods

This drug utilization study investigated prescription PGx drug use in 56,065 young individuals with different severe mental disorders (SMD) in the Danish iPSYCH sample (born 1981-2005). We investigated the number of PGx drug users (incidence, prevalence), age (at first PGx drug use), sex, multiple PGx drugs per user (in light of panel-based PGx testing) and concomitant use of PGx drugs (in light of combinatorial PGx testing).

Results

We identified substantial PGx drug use in terms of incidence rates (e.g. 333 per 10,000 person years for the anticonvulsant lamotrigine) and prevalence (e.g. 15,260 users for the antidepressant citalopram) in patients with SMD. The age of first time PGx drug use ranged from 11.6-20 years, depending on SMD and sex. On average, more than one PGx drug was used by a single person (range 1.6-5.6 drugs, depending on SMD) or even used concomitantly (41-69%) affecting mostly two different PGx genes (84-92% of concomitant PGx drug users).

Conclusions

PGx drugs were frequently used in young individuals with SMD, often subsequently and concomitantly, arguing for panel-based/combinatorial PGx testing over single-gene testing. PGx testing could be applied already at a very young age.

Disclosure

We thank the iPSYCH consortium, in specific the iPSYCH PI’s (Merete Nordentoft, Anders Børglum, Preben B. Mortensen, Ole Mors, Thomas Werge and David M. Hougaard). The iPSYCH project is funded by the Lundbeck Foundation Denmark and the universities and un

Keywords

PharmacogeneticsDrug Utilizationsevere mental disorders
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S143 - S144
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.